Abstract
The efficacy of neuraminidase inhibitors on improvement of respiratory symptoms triggered by influenza in patients with pre-existing chronic respiratory diseases is unknown. This 2-week, randomized, open-label study evaluated intravenous peramivir 600 mg on two consecutive days (peramivir-repeat), peramivir 300 mg single dose (peramivir-single), and oral oseltamivir 75 mg twice daily for 5 days in patients with confirmed influenza and chronic respiratory diseases. Patients recorded symptom scores daily. The primary endpoint of cumulative area of time vs symptoms (CATVS) was expressed as an index value of area under the curve vs time of the total score of cough, sore throat, and nasal congestion from baseline to 2 weeks. Of 214 randomized patients, 209 (56% female, 77% aged <65 years, 94% outpatients, 91% bronchial asthma, 62% influenza A) received ≥1 dose of study drug. Mean (standard deviation) CATVS was similar for peramivir-repeat (782.78 [487.17]) vs peramivir-single (717.35 [347.55]; P = .4371), and for peramivir-repeat vs oseltamivir (856.34 [404.99]; P = 1.00). However, CATVS was significantly shorter for peramivir-single vs oseltamivir, with an estimated treatment difference (TD) of -145.07 (95% confidence interval: -28...Continue Reading
References
Oct 29, 2005·The Lancet Infectious Diseases·Ron Eccles
Dec 6, 2005·Antiviral Research·Shanta BantiaPooran Chand
Jan 6, 2006·Current Medical Research and Opinion·Jiang-Tao LinXiao-di Wu
May 31, 2007·Clinical Drug Investigation·S SinghP Ward
Apr 6, 2011·Antimicrobial Agents and Chemotherapy·Shigeru KohnoUNKNOWN S-021812 Clinical Study Group
Aug 10, 2011·Antimicrobial Agents and Chemotherapy·Shigeru KohnoUNKNOWN S-021812 Clinical Study Group
May 31, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yugo ShobugawaHiroshi Suzuki
Aug 22, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akira Watanabe
Sep 12, 2012·Pulmonary Medicine·Mutsuo Yamaya
Nov 1, 2012·Antiviral Therapy·Michael G IsonW James Alexander
Oct 8, 2013·Frontiers in Microbiology·Daisuke KuraiHajime Takizawa
May 14, 2014·Chemotherapy·Yuji TakemotoJun Matsumoto
Sep 5, 2014·Chest·Brendan J CanningUNKNOWN CHEST Expert Cough Panel
Oct 16, 2014·Antiviral Therapy·Richard WhitleyWilliam P Sheridan
Aug 9, 2016·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takuji KomedaJingoro Shimada
Nov 3, 2016·Antiviral Therapy·Yutaka SaishoJingoro Shimada
Feb 16, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sudhir VenkatesanJonathan S Nguyen-Van-Tam
May 26, 2017·Yonsei Medical Journal·Jonghoo LeeYee Hyung Kim
Jul 20, 2017·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Kazufumi TakamatsuAtsuko Hata
Aug 2, 2017·Open Forum Infectious Diseases·Shigeki NakamuraShigeru Kohno
Sep 16, 2017·Infectious Disease Clinics of North America·H Keipp Talbot
Sep 25, 2017·Allergology International : Official Journal of the Japanese Society of Allergology·Yasuhiro Gon, Shu Hashimoto
Dec 30, 2017·Expert Review of Anti-infective Therapy·Nobuo HirotsuTakao Shishido
Jul 11, 2018·Influenza and Other Respiratory Viruses·Nobuo HirotsuTakahiro Hasegawa
Jun 14, 2019·Critical Care : the Official Journal of the Critical Care Forum·Eric J ChowTimothy M Uyeki
Jul 22, 2019·Critical Care : the Official Journal of the Critical Care Forum·Andre C Kalil, Paul G Thomas
Aug 17, 2019·Scientific Reports·Nobuo HirotsuTakao Shishido